[Immunotherapy of cutaneous neoplasms].

Skin cancers are the most commonly diagnosed malignancies worldwide; however, effective treatment of advanced tumors was unavailable until recent years. In the past decade, the introduction of immune checkpoint inhibitors (ICIs), targeting CTLA-4, PD-1, PD-L1 and recently LAG-3, has revolutionized therapeutic strategies for advanced skin cancers and improved survival outcomes. In this review, we present the current therapeutic opportunities and future directions of immunotherapy in the management of malignant melanoma, cutaneous squamous cell carcinoma, basal cell carcinoma, and Merkel cell carcinoma, accompanied by a brief overview of their mechanisms of action. Ambrus L, Balatoni T. Immunotherapy of cutaneous neoplasms.